Abstract
I read with interest the fine review by Dr. Ronald McGlennen of miniaturization technologies (1). My colleagues and I applaud Dr. McGlennen’s focus on technology that may allow the hurdles of reimbursement, regulation, education, and utility to be addressed so that the fruits of the Human Genome Project can be realized as improved therapeutics and diagnostics.

This publication has 2 references indexed in Scilit: